Omalizumab response in patients with chronic idiopathic urticaria: Insights from the XTEND-CIU study - 14/03/18
Doi : 10.1016/j.jaad.2017.10.010
Thomas B. Casale, MD a, Patrick H. Win, MD b, c, Jonathan A. Bernstein, MD d, e, Karin Rosén, MD f, Michael Holden, MD, MS f, ⁎ 
, Ahmar Iqbal, MB, BS, MBA f, Benjamin L. Trzaskoma, MS f, Ming Yang, PhD f, Evgeniya N. Antonova, MS, PhD f, Thomas Murphy, MD g, Mark D. Scarupa, MD h, Howard Sofen, MD i, Allen Kaplan, MD j
, Ahmar Iqbal, MB, BS, MBA f, Benjamin L. Trzaskoma, MS f, Ming Yang, PhD f, Evgeniya N. Antonova, MS, PhD f, Thomas Murphy, MD g, Mark D. Scarupa, MD h, Howard Sofen, MD i, Allen Kaplan, MD j a University of South Florida, Tampa, Florida
b The Clinical Research Center of Southern Illinois, Shiloh, Illinois
c Washington University School of Medicine, St. Louis, Missouri
d Bernstein Clinical Research Center, Cincinnati, Ohio
e University of Cincinnati, Cincinnati, Ohio
f Genentech, Inc, South San Francisco, California
g Charleston ENT and Allergy, Charleston, South Carolina
h Institute for Asthma & Allergy, Chevy Chase, Maryland
i University of California Los Angeles School of Medicine, Los Angeles, California
j Medical University of South Carolina, Charleston, South Carolina
∗Correspondence to: Michael Holden, MD, MS, 1 DNA Way, South San Francisco, CA 940801 DNA WaySouth San FranciscoCA94080
| Supported by Genentech, Inc. Medical writing support for this manuscript was funded by Genentech, Inc, and Novartis Pharmaceuticals Corporation. |
|
| Disclosure: Dr Casale's university employer has received grants and consulting fees from Genentech, Inc, and Novartis. Dr Win is a principal investigator and/or collaborator for and has served as a speaker for Genentech, Inc. Dr Bernstein has served as a consultant, advisory board member, principal investigator, and/or collaborator for Genentech, Inc, and Novartis. In addition, he has received research grants from Genentech, Inc and Novartis; has pending research grants from both companies; and has served as a speaker and received honoraria for participating in speaker bureaus, symposia, and acting as an expert witness for both companies. Dr Rosén, Dr Holden, Dr Iqbal, Mr Trzaskoma, Dr Yang, and Dr Antonova are employees of Genentech, Inc. Dr Murphy has participated in speaker bureaus for Boehringer Ingelheim, Genentech, Inc, and Teva. Dr Scarupa has served as a speaker for Genentech, Inc. Dr Sofen has served as a consultant and speaker for Genentech, Inc, and Novartis, and has received honoraria from both companies. Dr Kaplan has performed adjudications of adverse events for Genentech, Inc, Novartis, and Sanofi-Aventis, and served on an ad hoc advisory board for CSL Behring. |
|
| All the authors interpreted the data, contributed to the writing, and approved the final version of the manuscript; Benjamin L. Trzaskoma and Ming Yang provided data analysis. |
|
| Parts of these data were previously presented at the following events: American Academy of Allergy, Asthma & Immunology Annual Meeting, Atlanta, GA, March 3-7, 2017; American Academy of Dermatology Winter Meeting, Orlando, FL, March 3-7, 2017; Academy of Managed Care Pharmacy Annual Meeting, Denver, CO, March 27-30, 2017; MauiDerm for Dermatologists, Maui, HI, March 20-24, 2017; and European Academy of Allergy and Clinical Immunology Congress, Helsinki, Finland, June 17-21, 2017. |
|
| Reprints not available from the authors. |
© 2017
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 78 - N° 4
P. 793-795 - avril 2018 Retour au numéro
Article précédent
- Comorbidities in rosacea: A systematic review and update
- Roger Haber, Maria El Gemayel
- Topical calcipotriol before ablative fractional laser-assisted photodynamic therapy enhances treatment outcomes for actinic keratosis in Fitzpatrick grades III-V skin: A prospective randomized clinical trial
- Jeong-Wan Seo, Ki-Hoon Song
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?